Merck & Co Inc
MRK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
75,000
Merck & Co Inc News & Analysis
stocks
The 10 best US dividend stocks
These undervalued stocks with reliable dividends are worth considering.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,963.50 | 29.20 | 0.33% |
| CAC 40 | 7,806.13 | 28.45 | -0.36% |
| DAX 40 | 23,988.39 | 229.11 | -0.95% |
| Dow JONES (US) | 44,895.12 | 6.80 | -0.02% |
| FTSE 100 | 9,071.01 | 49.30 | -0.54% |
| HKSE | 25,562.13 | 173.78 | 0.68% |
| NASDAQ | 21,175.03 | 66.72 | 0.32% |
| Nikkei 225 | 40,998.27 | 457.96 | -1.10% |
| NZX 50 Index | 12,910.74 | 57.28 | 0.45% |
| S&P 500 | 6,394.11 | 5.47 | 0.09% |
| S&P/ASX 200 | 8,697.70 | 30.80 | 0.36% |
| SSE Composite Index | 3,597.94 | 4.28 | 0.12% |